Viewing nowCombinationLina-glomet Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202400189 · Approved 2024.01.24 · Insurance code 643508770
Improves blood glucose control in patients with type 2 diabetes
This medication is used to assist in blood glucose control for patients with type 2 diabetes. It is particularly effective when taken in combination with linagliptin and metformin, and can help patients manage their blood glucose better alongside diet control and exercise therapy. This contributes to maintaining stable blood glucose levels for patients and aids in diabetes management.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this drug must be swallowed whole without splitting, crushing, grinding, or chewing. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients treated with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug similar to the patient's current dose of metformin hydrochloride, together with a total daily dose of linagliptin 5mg, should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from immediate-release metformin to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A) whose creatinine clearance (CrCl) is ≥ 45mL/min and < 60mL/min or whose estimated glomerular filtration rate (eGFR) is ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this drug may be used with metformin hydrochloride dose adjustment as described below, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to < 45mL/min or estimated glomerular filtration rate (eGFR) decreases to < 45mL/min/1.73m2, this drug should be discontinued immediately.
This medication can rarely lead to a serious condition known as lactic acidosis; therefore, caution should be exercised during its use. It should not be used in patients with allergies to its ingredients, type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, or severe liver dysfunction. Additionally, it should be avoided in acute conditions affecting renal function, such as dehydration, severe infection, acute myocardial infarction, and shock. This medication can cause hypoglycemia, so blood glucose should be carefully monitored, especially when used in conjunction with sulfonylureas or insulin, and other drug doses adjusted as necessary. Patients with impaired renal function should undergo renal function tests prior to administration and have their kidney status checked regularly. Patients with weakened heart function should also use it with caution, and if symptoms of severe pancreatitis, such as acute pancreatitis, arise, administration should be discontinued immediately. This medication should be swallowed whole without breaking, chewing, or crushing it, although the tablet coating may pass through the digestive system unchanged, which is normal. The metformin ingredient may lower vitamin B12 levels, so it is advisable to check for vitamin B12 deficiency during long-term use. This medication may interact with other drugs; therefore, inform your doctor or pharmacist if you are taking other medications. Women who are pregnant or breastfeeding should avoid using this medication and should consult their doctor if planning a pregnancy. The elderly may experience decreased renal function, so kidney status should be checked frequently, and treatment should start at the lowest effective dose. In cases of overdose, serious side effects such as gastrointestinal disturbances or lactic acidosis may occur, and immediate medical attention should be sought. Store this medication out of reach of children, protect it from moisture, and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness.
Yellow oval extended-release film-coated tablet
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.